NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free APGE Stock Alerts $50.31 -3.44 (-6.40%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$50.19▼$54.5950-Day Range$45.86▼$69.8052-Week Range$14.19▼$72.29Volume442,861 shsAverage Volume385,951 shsMarket Capitalization$2.94 billionP/E RatioN/ADividend YieldN/APrice Target$73.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Apogee Therapeutics alerts: Email Address Apogee Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.1% Upside$73.00 Price TargetShort InterestBearish14.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.64) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.91 out of 5 starsMedical Sector400th out of 921 stocksBiological Products, Except Diagnostic Industry60th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apogee Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.00% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 6.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APGE. Previous Next 2.5 News and Social Media Coverage News SentimentApogee Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Apogee Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.64) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -9.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -9.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Apogee Therapeutics Stock (NASDAQ:APGE)Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Read More APGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APGE Stock News HeadlinesMay 19 at 6:22 AM | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Trading Down 4%May 19 at 1:58 AM | americanbankingnews.comHead to Head Review: Apogee Therapeutics (NASDAQ:APGE) & SQZ Biotechnologies (NYSE:SQZ)May 16 at 6:56 AM | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Increase in Short InterestMay 16 at 2:10 AM | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) to Post Q2 2024 Earnings of ($0.59) Per Share, Wedbush ForecastsMay 15, 2024 | globenewswire.comApogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesMay 15, 2024 | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) Expected to Post Q1 2025 Earnings of ($0.63) Per ShareMay 15, 2024 | americanbankingnews.comWedbush Reaffirms Outperform Rating for Apogee Therapeutics (NASDAQ:APGE)May 14, 2024 | markets.businessinsider.comBuy Rating on Apogee Therapeutics: Promising Drug Developments and Strong FinancialsMay 13, 2024 | investorplace.comAPGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comApogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsMay 12, 2024 | americanbankingnews.comBank of America Initiates Coverage on Apogee Therapeutics (NASDAQ:APGE)May 12, 2024 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92May 11, 2024 | nasdaq.comB of A Securities Initiates Coverage of Apogee Therapeutics (APGE) with Buy RecommendationMay 8, 2024 | investorplace.comEarnings Superstars: 3 Stocks Primed to Outperform This QuarterMay 6, 2024 | globenewswire.comApogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceApril 16, 2024 | finance.yahoo.comWith 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big gunsApril 15, 2024 | finance.yahoo.comApogee Therapeutics, Inc. (APGE)March 29, 2024 | finance.yahoo.comKey Proteo Submits De Novo Application to FDA for its First Newborn Screening KitMarch 28, 2024 | msn.comGov. Youngkin vetoes bills that would legalize retail marijuana sales, increase minimum wageMarch 28, 2024 | finance.yahoo.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline ProgressesMarch 25, 2024 | globenewswire.comApogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesMarch 14, 2024 | benzinga.comTop 3 Health Care Stocks That Are Ticking Portfolio BombsMarch 13, 2024 | seekingalpha.comARM: Everything You Need To Know About The Lock-Up Expiry (Rating Upgrade)March 12, 2024 | finance.yahoo.comApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionSee More Headlines Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/19/2024Next Earnings (Estimated)8/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$73.00 High Stock Price Target$95.00 Low Stock Price Target$40.00 Potential Upside/Downside+45.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.14% Return on Assets-23.24% Debt Debt-to-Equity RatioN/A Current Ratio38.08 Quick Ratio19.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.71 per share Price / Book3.67Miscellaneous Outstanding Shares58,460,000Free Float28,735,000Market Cap$2.94 billion OptionableOptionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Comp: $1.17MMs. Jane Pritchett V. Henderson (Age 58)Chief Financial Officer Comp: $843.64kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Comp: $870.83kDr. Rebecca Dabora Ph.D. (Age 65)Chief Technical Officer Ms. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 48)General Counsel Ms. Emily CoxVP & Head of PeopleMs. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 48)Senior Vice President of Finance More ExecutivesKey CompetitorsVericelNASDAQ:VCELRecursion PharmaceuticalsNASDAQ:RXRXKymera TherapeuticsNASDAQ:KYMRADMA BiologicsNASDAQ:ADMACG OncologyNASDAQ:CGONView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 152,500 shares on 5/17/2024Ownership: 0.339%Comerica BankBought 6,470 shares on 5/17/2024Ownership: 0.015%California State Teachers Retirement SystemBought 4,693 shares on 5/16/2024Ownership: 0.054%Bayesian Capital Management LPBought 6,771 shares on 5/16/2024Ownership: 0.016%Kennedy Capital Management LLCBought 3,188 shares on 5/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions APGE Stock Analysis - Frequently Asked Questions Should I buy or sell Apogee Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apogee Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APGE shares. View APGE analyst ratings or view top-rated stocks. What is Apogee Therapeutics' stock price target for 2024? 8 analysts have issued 1-year price objectives for Apogee Therapeutics' shares. Their APGE share price targets range from $40.00 to $95.00. On average, they expect the company's share price to reach $73.00 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price. View analysts price targets for APGE or view top-rated stocks among Wall Street analysts. How have APGE shares performed in 2024? Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE shares have increased by 80.1% and is now trading at $50.31. View the best growth stocks for 2024 here. When is Apogee Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 26th 2024. View our APGE earnings forecast. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) issued its earnings results on Tuesday, March, 5th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. What ETFs hold Apogee Therapeutics' stock? ETFs with the largest weight of Apogee Therapeutics (NASDAQ:APGE) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Apogee Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.35%), Price T Rowe Associates Inc. MD (2.73%), Darwin Global Management Ltd. (1.94%), Affinity Asset Advisors LLC (1.38%), Jennison Associates LLC (0.71%) and Blackstone Inc. (0.54%). View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APGE) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.